SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 25, 2003
Sirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 0-27914 | 34-1697351 | ||
| (State or other jurisdiction of incorporation) | (Commission File No.) | (I.R.S. Employer Identification Number) |
2950 Wilderness Place
Boulder, Colorado 80301
(Address of principal executive offices)
Registrant’s telephone number, including area code: (303) 449-6500
Ribozyme Pharmaceuticals, Inc.
(Former name or former address, if changed since last report.)
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE
Effective July 25, 2003, R. Scott Greer joined the board of directors of Sirna Therapeutics, Inc. (the “Company”). Following this appointment, the Company’s board of directors consists of six members.
A copy of the press release issued by the Company on July 29, 2003 is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
| 99.1 | Press Release issued by the Company on July 29, 2003. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | July 29, 2003 |
Sirna Therapeutics, Inc. (Registrant) | ||
By: | /s/ Marvin Tancer | |
Name: | Marvin Tancer | |
Title: | Chief Financial Officer & Vice President of Operations | |
3
EXHIBIT INDEX
Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release issued by the Company on July 29, 2003. | |
4
